The past few weeks have been filled with exciting news for the cardiology community. Here are some of the top stories we've collected from around the Web:
67% of Adults Should Do This to Avoid Heart Attacks
According to a new study published in the Journal of the American Medical Association (AMA), the pool of candidates that can be treated with statins can be expanded to 67% of all U.S. adults between the ages of 40-75. It is projected that this could prevent an additional 161,560 cardiovascular events, including heart attack, stroke, and others.
The Lowdown on TAVR: As Risk Drops, Expectations Rise
Cardiovascular Business reports on the five-year results from the PARTNER I trial (Placement of Aortic Transcatheter Valves Trial), which show that 5 years after implant, "valves showed no signs of deterioration with durable hemodynamics." With risk down, GlobalData now projects that the compound annual growth rate for TAVR valves will increase 19.7% between 2013 and 2020.
New "Once-in-a-Decade" Novartis Drug for Heart Failure Approved by FDA
The Food and Drug Administration (FDA) has approved a new heart failure drug by Novartis, which has been met with considerable support from the medical community. The drug - Entresto - is the first in a new class of drugs called angiotensin receptor neprilysin inhibitors that is used to treat high blood pressure and congestive heart failure while enhancing neurohormonal systems.